Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10479MR)

This product GTTS-WQ10479MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10479MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7776MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ3538MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ13392MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ7523MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ14798MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ15768MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ15956MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ9462MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IPH4102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW